Lunit INSIGHT MMG
Lunit
Highlights suspected malignant lesions on mammography with a per-lesion and per-case abnormality score.
At A Glance
- Manufacturer
- Lunit
- Medical specialty
- Radiology
- Clearance route
- 510(k)
- Year authorized
- 2021 onward
- Modality
- Mammography
- Role in workflow
- Concurrent read
Lunit built its evidence base largely outside the United States, which is worth noting when reading its published performance. Large validation sets drawn from Korean and European screening populations differ from US screening populations in breast density distribution and in recall behavior, and both affect measured performance.
Where It Is Used
- Screening and diagnostic mammography support
- Case prioritization in high-volume programs
Limitations Worth Knowing
Breast density is the recurring confounder in mammography AI. Performance in dense tissue is consistently lower than aggregate figures suggest, and dense tissue is where the clinical need is greatest.
Regulatory status, indications, and labeling change over time. Confirm current status on the FDA's AI/ML-Enabled Medical Devices list and in the manufacturer's current instructions for use before relying on anything stated here.